Fig. 1
From: Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy
Timeline for the FDA and NMPA approval of small-molecule kinase inhibitors. The figure shows the small-molecule kinase inhibitors approved by the FDA and NMPA from 2001 to 2023. Except for the red star representing small-molecule inhibitors approved by NMPA, all others are FDA-approved. The green box shows tyrosine kinase inhibitors, while the pink box shows ser/thr kinase inhibitors, and the black box shows drugs with black box warnings. Green represents the incidence of cardiotoxicity events induced by small molecule inhibitors